Menu Search
PRODUCT CODE: EM1902-23

GATA3 Mouse Monoclonal Antibody [A3G6] (EM1902-23)

Applications

  • WB

  • FC

REACTIVITY

  • Human

-
+
Cart0
Western blot analysis of GATA3 on MCF-7 cell lysate. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (EM1902-23, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.<br /> Specific bands were detected for GATA3 full length (FL) at approximately 52 kDa and the splice form (SF) at approximately 39 kDa (as indicated).
  • Western blot analysis of GATA3 on MCF-7 cell lysate. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (EM1902-23, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.<br /> Specific bands were detected for GATA3 full length (FL) at approximately 52 kDa and the splice form (SF) at approximately 39 kDa (as indicated).
  • Flow cytometric analysis of GATA3 was done on jurkat cells. The cells were fixed, permeabilized and stained with the primary antibody (em1902-23, 1/100) (red). After incubation of the primary antibody at room temperature for an hour, the cells were stained with a Alexa Fluor 488-conjugated goat anti-Mouse IgG Secondary antibody at 1/500 dilution for 30 minutes.Unlabelled sample was used as a control (cells without incubation with primary antibody; blcak).
Western blot analysis of GATA3 on MCF-7 cell lysate. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (EM1902-23, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.
Specific bands were detected for GATA3 full length (FL) at approximately 52 kDa and the splice form (SF) at approximately 39 kDa (as indicated).

Applications

  • WB

  • FC

REACTIVITY

  • Human

SPECIFICATIONS

Product Type

Mouse monoclonal primary

Product Name

GATA3 Mouse Monoclonal Antibody [A3G6] (EM1902-23)

Immunogen

Synthetic peptide corresponding to n terminal of human gata3.

Host

Mouse

Positive Control

MCF-7 cell lysates, jurkat.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

A3G6

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

2 ug/ul

PURIFICATION

Protein A purified.

MOLECULAR WEIGHT

Predicted band size 48 kDa

Isotype

IgG1

APPLICATION DILUTION

  • WB

  • 1:1,000-1:5,000

  • FC

  • 1:50-1:100

TARGET

UNIPROT #

P23771

PROTEIN NAME

GATA3

SYNONYMS

GATA 3 antibody; GATA binding factor 3 antibody; GATA binding protein 3 antibody; GATA-binding factor 3 antibody; Gata3 antibody; GATA3_HUMAN antibody; HDR antibody; HDRS antibody; MGC2346 antibody; MGC5199 antibody; MGC5445 antibody; Trans acting T cell specific transcription factor GATA 3 antibody; Trans-acting T-cell-specific transcription factor GATA-3 antibody

TISSUE SPECIFICITY

T-cells and endothelial cells.

SUBCELLULAR LOCATION

Nucleus.

FUNCTION

GATA3 is a transcription factor that in humans is encoded by the GATA3 gene. Studies in animal models and humans indicate that it controls the expression of a wide range of biologically and clinically important genes. The GATA3 transcription factor is critical for the embryonic development of various tissues as well as for inflammatory and humoral immune responses and the proper functioning of the endothelium of blood vessels. GATA3 haploinsufficiency (i.e. lose of one or the two inherited GATA3 genes) results in a congenital disorder termed the Barakat syndrome. Current clinical and laboratory research is focusing on determining the benefits of directly or indirectly blocking the action of GATA3 in inflammatory and allergic diseases such as asthma. It is also proposed to be a clinically important marker for various types of cancer, particularly those of the breast. However, the role, if any, of GATA3 in the development of these cancers is under study and remains unclear.